Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.

@article{Offner2015FrontlineRC,
  title={Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.},
  author={Fritz C. Offner and Olga S Samoilova and Evgenii A Osmanov and H Eom and Max S. Topp and Jo{\~a}o Filipe Raposo and Viacheslav Pavlov and Deborah Sokol Ricci and Shalini Chaturvedi and Eugene Zhu and Helgi J K van de Velde and Christopher Enny and Aleksandra Rizo and Burhan Ferhanoğlu},
  journal={Blood},
  year={2015},
  volume={126 16},
  pages={1893-901}
}
This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method). In total, 164 patients were randomized 1:1 to receive six 21-day cycles of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), and doxorubicin 50 mg/m(2… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 20 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis

Annals of Hematology • 2018
View 13 Excerpts
Highly Influenced

Precision medicine in diffuse large B-cell lymphoma: Hype or hope?

European journal of cancer • 2016
View 12 Excerpts
Highly Influenced

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Ferreri
Resistance to Targeted Anti-Cancer Therapeutics • 2018
View 1 Excerpt

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Annals of oncology : official journal of the European Society for Medical Oncology • 2017

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 11 Excerpts
Highly Influenced

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 11 Excerpts
Highly Influenced

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine • 2008
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…